High Mol Wt Research Articles

Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells.

The expression levels of different vascular endothelial growth factor A (VEGF) isoforms are associated with the angiogenesis and the patient's prognoses in human cancers. Ribosomes specifically scan from 5' to 3' CUG initiation codon in the long 5'-untranslated region (5'-UTR) of the VEGF mRNA, resulting in the generation of high mol wt VEGF isoform [call large VEGF (L-VEGF)]. Alternative splicing of VEGF mRNA transcripts results in several isoforms with distinct properties that are dependent up their exon compositions. In this study, we observed two novel kinds of splicing VEGF isoforms that transcripted at the first upstream CUG codon, and which we have named large-VEGF144 (LVEGF144), and large-VEGF138 (L-VEGF138). The expression levels of messenger RNA for the different VEGF splice forms were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). After DNA sequencing, the genetic structure of L-VEGF144 involved not only a partial exon 1, exon 6a, and exons 7-8, but also an unique 108- nucleotides insertion of VEGF intron 5 interposed between exon 1 and exon 6. At the same time, L-VEGF144 lacked most of the Nterminal fragments (exons 1-5). We further found that a specific detection model could easily and rapidly confirm the presence of L-VEGF144 mRNA fragments in the biopsies or cell lines via RT-PCR assay. In addition, we used visible fluorescent fusion proteins to prove that both L-VEGF144 and L-VEGF138 have nuclear localization ability. Taken together, the findings of this study indicate that, unlike previously identified isoforms, these novel VEGF isoforms are likely to suggest a further level of complexity in the angiogenic process.

Abstract 2883: Enhanced anti-tumor activity and bioavailability of chemopreventives by coated polymeric implants

Abstract Poor oral bioavailability limits the use of many chemopreventives in the prevention and treatment of cancer. We previously reported a novel concept in which polycaprolactone (PCL) implants embedded with test agents provide sustained delivery for long duration (months to >1year), reduce effective dose substantially and increase bioavailability. While tested successfully for various agents, this formulation results in an initial burst release and does not apply to heat-labile compounds. Furthermore, it takes 2 or more years for the polymeric implant to biodegrade. To overcome these limitations, we hypothesized that formulation of low mol wt polymeric implants will provide more sustained and higher release compared with higher mol. wt polymers; the low mol. wt polymers are also expected to biodegrade in weeks to months. To test part of this hypothesis, we used three different mol wt PCL polymers and two co-polymers, poly(D, L-lactide-co-glycolide) (PLGA). The method involves i) preparation of blank PCL implants (1.4 mm dia), and ii) coating of 30-40 layers by dipping blank implants, with intermittent drying, in 10-20% of different mol wt PCL solutions in dichloromethane containing 10% curcumin in tetrahydrofuran. The curcumin implants when tested for in vitro release showed that i) the burst release effect and the amount released varied with mol wt of the polymer. Implants prepared with PCL of 3,600 mol wt (PCL-3.6K) did not show any burst release phenomenon. Instead, these implants took nearly 7 days to render maximum daily release and thereafter the rate of release declined gradually over a period of two weeks. Implants prepared from higher mol wt polymers (PCL-31K and PCL-112K) were accompanied with some initial burst release and the rate of release declined gradually. Cumulative release measured over two weeks was found to be inversely proportional to the mol wt of PCL: PCL-3.6K (30%) > PCL-31K (24%) > PCL-112K (21%). On the other hand, the co-polymers, PLGA (50:50) and PLGA (75:25) showed only 1% and 0.5% total release, respectively. To determine if the implant delivery reduced the effective dose in a tumor model, nude mice were inoculated with human lung cancer (A549) cells and then treated with coated implants of withaferin A, a potent triterpenoid isolated from the traditional Ayurvedic herb “Ashwagandha”. Withaferin A given via the coated implants significantly inhibited (>50%) human lung cancer (A549) xenograft, while it was ineffective when the same dose was administered i.p. Together, our data suggest that coated implants of low mol wt PCL can accommodate heat-labile compounds, enhance bioavailability, furnish more sustained and higher cumulative release, and elicits anti-tumor activity. Our ultimate goal is to use low mol polymeric implants that will biodegrade in few months and provide continuous release of the drug. (Supported from CA-118114, KLCRP and Duggan Endowment). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2883. doi:1538-7445.AM2012-2883

The enzymatic incorporation of isopentenyl pyrophosphate into polyisoprene in rubber particles from Parthenium argentatum Gray

Studies have indicated the presence of both a de novo biosynthesis of new polyisoprene chains and the elongation of pre-existing rubber-PP chains in rubber particles from Ficus elastica Roxb. and small rubber particles from Hevea brasiliensis (Willd. ex A. Juss.) Müll. Arg. In this paper, we have isolated rubber particles from the cortical parenchyma of Parthenium argentatum Gray with an adsorbed isopentenyl pyrophosphate isomerase that was competent to form polyisoprene to determine the presence of de novo biosynthesis of polyisoprene and the elongation of pre-existing rubber-PP. The gel filtrated rubber particles were supplied saturating concentrations of [ 14C]-isopentenyl pyrophosphate for 1 h and the resulting concentrations of [ 14C]-polyisoprene were isolated and analyzed with a Waters 150C Gel Permeation Chromatograph. The mol wt distribution of the [ 14C]-polyisoprene ranged from 10 3 to 10 6 Da with no formation of high mol wt chains equal to the polyisoprene in the mol wt distribution of natural rubber from P. argentatum. The mol wt distribution of [ 14C]-polyisoprene following 1 h of incubation of the reaction mixture was similar to the mol wt distribution formed by the bound rubber transferase in washed rubber particles of H. brasiliensis and the time-dependent formation of polyisoprene by washed rubber particles from P. argentatum. The data support the conclusion that the washed rubber particles from P. argentatum contain a bound rubber transferase that initiates the formation of new chains of polyisoprene from the dimethylallyl pyrophosphate initiator generated from the added isopentenyl pyrophosphate isomerase followed by the extensive polymerization of isopentenyl pyrophosphate to form a monomodal rubber polymer. There was no evidence in these washed rubber particles of a chain elongation of pre-existing rubber-PP.

Development characterizations and evaluation of Poly(-ϵ-caprolactone)-based microspheres for hepatitis B surface antigen delivery

The major disadvantage of several currently available vaccines is the need for repeated administrations. The aim of the study was to develop long-acting microspheres based on poly(-ϵ-caprolactone) (PCL) for delivery of recombinant hepatitis B surface antigen (rHBsAg). PCL microspheres were prepared for induction of humoral and cellular immunity by intramuscular administration. Microspheres were characterized for their size, shape, incorporation efficiency, zeta potential, antigen integrity, antigen conformation and immunogenicity. DSC (Differential Scanning Calorimetry) studies revealed that better encapsulation efficiency between high and low mol wt polymer. The Circular Dichorism spectroscopy (CD) of antigen, released from PCL microspheres revealed that the secondary structure of antigen was unperturbed. Antigen integrity was evaluated by SDS-PAGE. Immunization with HBsAg PCL microspheres resulted in upregulation of specific cellular (IFN-γ and IL-2) as well as IgG response in BALB/c mice. Immune responses were found significantly higher than the conventional alum adjuvant following a single intramuscular immunization. These results highlight the enhanced efficiency of these PCL microspheres as an adjuvant and their prospective use in the prevention of hepatitis B.

Maternal Overweight Programs Offspring Insulin and Adiponectin Signaling

Maternal overweight (OW) was induced in rats by overfeeding via total enteral nutrition. Male offspring from OW dams gained greater (p < 0.005) body weight and %fat mass assessed by NMR, X‐ray CT and adipose tissue weights when fed high fat diet (45% fat). Hepatic microarray analyses at postnatal day 21 revealed 147 transcripts were significantly (±1.8‐fold, p < 0.05) altered by maternal OW, including expression of 20 known SREBP‐1‐regulated transcripts. Expression of SREBP‐1 mRNA and lipogenic transcripts was confirmed using real‐time PCR. Increased nuclear levels of SREBP‐1 and recruitment to the FASN promoter were confirmed via ELISA and ChIP analyses, respectively. Decreased expression of 10 PPARα regulated genes including FGF21 was also uncovered. FGF21 serum levels were lower (p< 0.05) in OW dam offspring. Further serum levels of high mol wt adiponectin (p < 0.05) were decreased in OW dam offspring at weaning. While no changes in %fat mass or adipose tissue adiponectin mRNA were observed, hepatic expression of AdipoR1 and R2 were lower in OW dam offspring. Finally, phosphorylation of the adiponectin target AMPK was significantly decreased in livers of OW dam offspring. Our data suggest that maternal OW at conception leads to increased lipogenic gene expression in concert with decreased PPARα‐adiponectin‐AMPK signaling in the liver of young offspring. Support ARS‐CRIS 6251‐51000‐005‐00D and R01‐DK084225.

Protein-leakage during heparin – induced <i>in-vitro</i> capacitation of bull sperm

Abstract. Freshly ejaculated washed spermatozoa of six cross-bred bulls were capacitated by incubating in TALP medium supplemented with BSA, heparin and hepes buffer at a sperm concentration of 6 × 109 s/ml at 37ο C for 6 h. A control was also run in 0.85% saline. Percentage motility was observed at two h interval. Sperm smears were stained with giemsa and observed under oil emulsion to study different stages of acrosome reaction. After six h of incubation, sperm membrane proteins were extracted from capacitated- and uncapacitated- spermatozoa using deoxycholate in Tris-HCl (0.02M). Spermatozoa, incubation media (IM) and sperm membrane extract (SME) were analyzed for total proteins which were further fractionated by SDS-PAGE. Antisera raised against SME of bull # 1, 2 and 3 were used for identification of antigens in SME of all the bulls using immunodiffusion technique. After incubation of spermatozoa for 6 h, there was 15–21% and 55–62% decline in motility of capacitated- and uncapacitated- spermatozoa respectively. A total of 62–87% spermatozoa showed acrosome reaction (swelling, vesiculation and shedding of acrosome) in all the bulls. A statistically significant (P<0.05) decrease in protein content of spermatozoa was observed during capacitation. The percentage extraction of protein and percentage leakage of proteins into medium showed a significant correlation with percentage acrosome reaction in respective bulls. A higher and positive correlation of rate of acrosome reaction with protein content of capacitated- and uncapacitated- spermatozoa and IM indicates that percentage capacitation in correlation to fertility can be predicted from the protein content of spermatozoa and proteins released into the medium. Protein profile revealed that from 12.5 to 70 kDa proteins get exposed during capacitation. There was leakage of 4–7 proteins, mainly of medium (70–130 kDa) and low mol wt (<12.5–35 kDa) from capacitated spermatozoa, whereas only 2–5 proteins of high (160–>240 kDa) and low (<12.5–25 kDa) mol wt proteins get leaked out from uncapacitated spermatozoa. Immunodiffusion reaction of SME of bull # 1, 2 and 3 also suggested the removal/exposure of antigens from sperm surface during capacitation and acrosome reaction.

Addition of polyglycol to old culture of Phanerochaete chrysosporium.

Polyglycols increased lignin peroxidase activity in shaken cultures of Phanerochaete chrysosporium even when they were added to an old fungus (5 or 10 d after inoculation). The effects depended on the polyglycol mol wts (10(2)-10(6) Daltons) as well as on the backbone structure (i.e., poly[ethylene glycol], poly[butylene glycol], poly[propylene glycol]) and terminal groups (i.e., poly[ethylene glycol], poly[ethylene glycol] methyl ether, poly[ethylene glycol] dimethyl ether). The residual quantity of polyglycol in the biomass and in the culture filtrate also varied among different polyglycols. The polyglycols act after being adsorbed to the cell membrane exaggerating the asymmetry of the membrane environment. In old fungus, the incompatibility of polyglycols and glycans decreases the adsorption and the effect of high mol wt polyglycols.

Synthesis and characterization of hyaluronan-based polymers for tissue engineering.

Hyaluronan (HA) is a naturally occurring, negatively charged high mol-wt glycosaminoglycan (GAG), that is composed of repeated disaccharide units of D-glucuronic acid and N-acetylglucosamine. It is the only GAG that lacks an associated protein moiety and sulfate groups. HA is a highly conserved and widely distributed polysaccharide. In a variety of mammalian tissues, it exerts structural functions because of its peculiar physicochemical properties. Because of its propensity to form highly hydrated and viscous matrices, HA imparts stiffness, resilience, and lubrication to tissues. The unique properties of HA are manifested in its mechanical function in the synovial fluid, the vitreous humor of the eye, and the ability of connective tissue to resist compressive forces, as in articular cartilage.

CD44--a sticky target for asthma.

CD44--a sticky target for asthma.

Preparation of polysaccharide-conjugate vaccines.

It was recognized early last century that small molecules, known as haptens, can be made immunogenic after conjugation to carrier proteins (). This principle has since been applied successfully to improve the immunogenicity of (poly)saccharides (,). We now know that the carrier proteins ensure the involvement of T-helper lymphocytes in the activation of the hapten- or polysaccharide-specific antibody-producing B lymphocytes (Fig. 1). In contrast to small molecules or haptens, polysaccharides (or other macromolecules with a repeating structure) are able to induce an immune response, most likely by directly activating B-lymphocytes. Antigens that are able to induce an immune response without the involvement of T-helper lymphocytes are referred to as TI (thymus-independent) antigens () (Table 1). TI-2 antigens, such as plain polysaccharides, are not able to activate relatively immature B-cells. This is in contrast to TI-l antigens, which can activate immature B-cells because of their mitogenic activity. Lipopolysaccharides (LPS) are examples of TI-l antigens. Conventional T-cells recognize peptide sequences in association with the major histocompatibility complex (MHC). Recently, unconventional T-cells were found to recognize (glyco) lipids in a CD1-restricted way, γδT-cells were shown to respond to non-proteinaceous microbial ligands (that may include carbohydrates) in a virtually MHC-unrestricted way (). The findings of T-cell regulation of the immune response against polysaccharides (, , ) without biochemical demonstration of the specificity of the molecular interactions can best be explained by assuming a role for anti-idiotypic antibodies and T-cells specific for the idiotopes (carbohydrate mimotopes) or via the newly discovered unconventional T-cells. Open image in new window Fig. 1. Polysaccharides are poor in activating B-cells to the production of antibodies in children younger than 2 yr of age. If antibodies are formed, they are of short duration. For conjugate vaccines T-cells are involved in the activation of B-cells. Presumably, the conjugate is taken up by polysaccharide-specific B-cells, processed, and presented to carrier-specific T-cells. The involvement of T-cells results in the activation of B-cells to production of antibodies and induction of memory in children younger than 2 yr of age. Table 1 Characteristics of T-Cell Independent Antigens Type 1 Bacterial cell-wall components Mitogenic or polyclonal B-cell activator Stimulate antibody responses in neonates Stimulate antibody responses in CBA/N mice Examples: lipopolysaccharide and hapten derivatives; Brucella abortus Type 2 Polysaccharides, polypeptides, polynucleotides High mol wt, multiple repeating antigenic determinants Slowly metabolized Tolerogenic in large doses or soluble form Activate alternative complement pathway (some) Generate few (if any) memory B-cells Restriction of isotypes induced Lack of affinity maturation Lack of T-cell memory Fail to stimulate antibody responses in neonates Fail to stimulate antibody responses in CBA/N mice Examples: Pneumococcal polysaccharides; Haemophilus influenzaetype b polysaccharide; meningococcal polysaccharides

Characterization of Inhibin Forms and Their Measurement by an Inhibin α-Subunit ELISA in Serum from Postmenopausal Women with Ovarian Cancer

The aim of this study was to characterize the molecular wt forms of inhibins A and B and its free alpha-subunit present in serum from women with ovarian cancer as a basis for developing improved monoclonal antibody-based inhibin assays for monitoring ovarian cancer. Three new inhibin alpha-subunit (alphaC) ELISAs were developed using monoclonal antibodies directed to three nonoverlapping peptide regions of the alphaC region of the inhibin alpha-subunit. To characterize serum inhibin molecular wt forms present in women with ovarian cancer, existing inhibin immunoassays (inhibin A, inhibin B, and pro-alphaC) and the new alphaC ELISAs were applied to sera from women with granulosa cell tumors and mucinous carcinomas previously fractionated using a combined immunoaffinity chromatography, preparative SDS-PAGE, and electroelution procedure. The distribution and molecular size of dimeric inhibins and alpha-subunit detected were consistent with known mol wt forms of inhibins A and B and inhibin alpha-subunit and their precursor forms present in serum and follicular fluid from healthy women. The alphaC ELISAs recognized all known forms of inhibin and the free inhibin alpha-subunit, although differences between alphaC ELISAs were observed in their ability to detect high mol wt forms. To assess which of the alphaC ELISAs was preferred in application to ovarian cancer, the alphaC ELISAs were applied to serum from a range of normal postmenopausal women (n = 61) and postmenopausal women (n = 152) with ovarian (serous, mucinous, endometrioid, clear cell carcinomas, and granulosa cell tumors) and nonovarian (breast and colon) cancers. Despite differences in their ability to detect high mol wt forms of inhibin, the alphaC ELISAs showed similar sensitivity (i.e. proportion of cancer patients correctly detected) and specificity (proportion of controls correctly detected) indexes in the detection of mucinous carcinomas (84% and 95%) and granulosa cell tumors (100% and 95%) compared with earlier inhibin RIA or polyclonal antibody-based immunofluorometric assays. A combination of the alphaC ELISAs with the CA125 assay, an ovarian tumor marker that has a high sensitivity and specificity for other ovarian cancers (serous, clear cell, and endometrioid), resulted in an increase in sensitivity/specificity indexes (95% and 95%) for the all ovarian cancer group. These new monoclonal antibody-based inhibin alphaC ELISAs now provide practical and sensitive assays suitable for evaluation as diagnostic tests for monitoring ovarian cancers.

Controlled release of water-soluble polymeric complexes of sorbic acid with antifungal activities.

We synthesized six water-soluble polymeric complexes of sorbic acid with polyvinylpyrrolidone of different molecular weight (mol wt). As shown by infrared absorption spectrum analysis, the complexes were formed by hydrogen bonding. The complexes (SC1, with mol wt=10 kDa, SC2 with mol wt=25 kDa, SC3 with mol wt=30 kDa, SC4 with mol wt=40 kDa, SC5 with mol wt=90 kDa, and SC6 with mol wt=360 kDa) were characterized as low mol wt (SC1, SC2, and SC3) and high mol wt (SC4, SC5, and SC6). The antifungal potencies of the complexes were tested by the macrodilution susceptibility method against environmental and clinically important fungi. Sorbic acid as well as the complexes exhibited minimum inhibitory concentrations (MICs) lower than potassium sorbate against all the strains tested. MICs of SC1, SC2, and SC3 were shown to be 2- to 4-fold lower for yeast and 1.5- to 3-fold lower than those of sorbic acid for moulds, respectively. The MICs of SC4 and SC5 against both of the Candida species tested ranged from 500 to 800 microg/ml, whereas for SC6 and sorbic acid they were about 1 mg/ml. The potencies of the high mol wt complexes against moulds were decreased by increasing the mol wt. For both of the moulds tested, the MICs of SC4 were slightly lower than those of sorbate. The MICs of sorbic acid and SC5 were equal to 300 microg/ml and 500 microg/ml respectively for Aspergillus parasiticus and for Penicillum viridicatum. The susceptibility to SC6 of all of the hyphomycetes tested was higher than that to sorbic acid. The low mol wt complexes and the sorbic acid exhibited minimal fungicidal concentrations (MFCs) 2 and 3 times higher respectively than the MICs. Sorbic acid and SC3 at a concentration of 2.5 mg/ml in an in vitro time kill curve study of Candida tropicalis were shown to be fungistatic, whereas SC1 and SC2 were fungicidal at the same concentrations. For Aspergillus parasiticus sorbic acid at 2.5 mg/ml was fungistatic for a 24-h period, whereas SC1, SC2, and SC3 were fungicidal.

New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation.

We recently demonstrated that the very long 5'-untranslated region (5'-UTR) of the vascular endothelial growth factor (VEGF) mRNA contains two independent internal ribosome entry sites (IRES A and B). In the human sequence, four potential CUG translation initiation codons are located in between these IRES and are in frame with the classical AUG start codon. By in vitro translation and COS-7 cell transfections, we demonstrate that a high mol wt VEGF isoform [called large VEGF (L-VEGF)] is generated by an alternative translation initiation process, which occurs at the first of these CUG codons. Using a bicistronic strategy, we show that the upstream IRES B controls the translation initiation of L-VEGF. This isoform is 206 amino acids longer than the classical AUG-initiated form. With a specific antibody raised against this NH2 extension, we show that the L-VEGF is present in different mouse tissues or in transfected COS-7 cells. We also demonstrate that L-VEGF is cleaved into two fragments: a 23-kDa NH2-specific fragment and a fragment with an apparent size similar to that of the classical AUG-initiated form. This cleavage requires the integrity of a hydrophobic sequence located in the central part of the L-VEGF molecule. This sequence actually plays the role of signal peptide in the classical AUG-initiated form. The AUG-initiated form and the COOH cleavage product of the L-VEGF are both secreted. In contrast, the large isoform and its NH2 fragment present an intracellular localization. These data unravel a further level of complexity in the regulation of VEGF expression.

Characterization of human FSH isoforms reveals a nonglycosylated beta-subunit in addition to the conventional glycosylated beta-subunit.

Human FSH consists of a mixture of isoforms that can be separated on the basis of differences in negative charge conferred by variations in the numbers of sialic acid residues that terminate oligosaccharide branches. Western analysis of human FSH isoforms separated by chromatofocusing revealed the presence of two human FSHbeta isoforms that differed in size. A low mol wt human FSHbeta isoform was associated with all FSH isoform fractions. A high mol wt human FSHbeta isoform was associated with the more acidic fractions and increased in relative abundance as the pI decreased. Characterization of representative human FSHbeta isoforms by mass spectrometry and automated Edman degradation revealed a low mol wt isoform that was not glycosylated. A high mol wt isoform was N-glycosylated at Asn residues 7 and 24. These results indicate that pituitary human FSH consists of two classes of molecules: those that possess a nonglycosylated beta-subunit and those that possess a glycosylated beta-subunit. Glycoprotein hormones are known to be elliptical molecules, and the beta-subunit oligosaccharides project outward from the short diameter, thereby increasing it. It is interesting to speculate that this change in shape might affect ultrafiltration rates, leading to differences in delivery rates to target tissues and elimination by filtration in the kidney.

Activation and transforming growth factor-beta production in eosinophils by hyaluronan.

To investigate whether extracellular matrix glycosaminoglycan hyaluronan (HA) modulates eosinophil activation and transforming growth factor (TGF)-beta production by eosinophils, human peripheral blood eosinophils (purity > 99%) from 12 patients with mild to moderate asthma or six healthy subjects were isolated and incubated with increasing concentrations of low molecular weight (mol wt) HA ( approximately 0.2 x 10(6) D) or high mol wt HA (3.0 to approximately 5.8 x 10(6) D). We found that the low mol wt HA has a pronounced effect on eosinophil survival in both patients with asthma and healthy subjects in a dose-dependent fashion on Days 2 and 4. Whereas the high mol wt HA had a smaller effect on eosinophil survival than did the low mol wt HA. The HA-mediated eosinophil survival was partially but significantly inhibited ( approximately 50% inhibition) by a blocking monoclonal antibody for CD44, a specific receptor of HA, and largely inhibited by an anti-granulocyte macrophage colony-stimulating factor (GM-CSF) neutralizing antibody but not by an anti-interleukin (IL)-3 or anti-IL-5 neutralizing antibody. In addition, the low mol wt HA increased GM-CSF messenger RNA (mRNA) expression and protein secretion by eosinophils in a dose-dependent fashion, suggesting that the HA-mediated eosinophil survival is due mainly to induction of GM-CSF release through partial CD44 signaling. Furthermore, we demonstrated that the low mol wt HA results in morphologic changes in eosinophils such as transforming from a round to a spindle shape and in homotypic aggregation, upregulates intercellular adhesion molecule-1 expression, and increases TGF-beta mRNA expression and protein secretion by eosinophils. These observations suggest previously unforeseen interactions between eosinophils and low mol wt extracellular matrix and, thus, novel pathways by which eosinophils may contribute to the regulation of airway inflammation and airway remodeling.

Evidence for alternative pathways of granulosa cell death in healthy and slightly atretic bovine antral follicles.

Granulosa cell death is an early feature of atresia; however, there are many apparent contradictions in the literature concerning the mode of granulosa cell death. We have therefore examined this process in bovine healthy and atretic antral follicles, using a variety of established techniques. Light and electron microscopic observations indicated the presence of pyknotic or shrunken nuclei in both the membrana granulosa and the antrum. In the membrana granulosa, these nuclei were frequently crescent shaped and uniformly electron dense and were approximately the same size as healthy nuclei, all of which are typical of early apoptosis. However, these nuclei were within the membranes of a healthy granulosa cell, suggesting that phagocytosis by a neighboring granulosa cell is an unusually early event in the apoptotic pathway of granulosa cells. In the membrana granulosa, pyknotic nuclei stained intensely with hematoxylin but weakly with the DNA-intercalating stain propidium iodide. A percentage of these pyknotic nuclei stained by TUNEL (terminal deoxy-UTP nick end-labeling). However, in the antrum, the pyknotic nuclei and larger globules of DNA stained intensely with both hematoxylin and propidium iodide, but were not TUNEL positive. The comet assay of cell death produced a streak tail of randomly nicked DNA, rather than the plume of low mol wt apoptotic DNA. Globules collected from fresh follicular fluid stained intensely with propidium iodide and were shown by PAGE to contain DNA, the majority of which was high mol wt. In conclusion, granulosa cells within the membrana granulosa die by apoptosis, with phagocytosis by a neighboring cell preceding any potential budding of the nucleus or cell itself. Granulosa cells near the antrum are sloughed off into the antrum, and their death has features more consistent with that of other cell types that undergo death as a result of terminal differentiation.

Two novel cysteine substitutions (C1263R and C1995S) of thyroglobulin cause a defect in intracellular transport of thyroglobulin in patients with congenital goiter and the variant type of adenomatous goiter.

We analyzed the thyroglobulin (Tg) gene of 2 unrelated patients with congenital goiter and the Tg gene of 2 siblings with the variant type of adenomatous goiter. The clinical characteristics of the patients with congenital goiter and the variant type of adenomatous goiter were very similar, except for serum Tg levels, which were less than 15 pmol/L in the patients with congenital goiter, but 117-181 pmol/L in the patients with the variant type of adenomatous goiter (normal, 15-50 pmol/L). The tissue content of Tg in the thyroid glands of all 4 patients was reduced at 0.9-3.8% of total protein (normal, 19-40%). The missense mutation C1263R was detected in the 2 unrelated patients with congenital goiter; the pedigree study showed an autosomal recessive pattern of inheritance. In the 2 siblings with the variant type of adenomatous goiter, the missense mutation C1995S was homozygously detected. In the Tg complementary DNA of 110 normal subjects, the allelic frequencies of the C1263R and C1995S mutations were each less than 0.5%. Also in the normal subjects were detected 35 nucleotide polymorphisms, the insertion of 3 nucleotides, and 1 alternative splicing, each of which was not associated with any specific thyroid disease. From these data, the molecular mechanism of the C1263R and C1995S mutations was elucidated. We first analyzed the carbohydrate residues of C1263R Tg and C1995S Tg. Sensitivity to treatment by endoglycosidase H suggests that C1263R Tg and C1995S Tg were retained in the endoplasmic reticulum (ER). Also, the presence of endoglycosidase H-resistant Tg as well as endoglycosidase H-sensitive Tg in the patients with the variant type of adenomatous goiter suggests that a fraction of C1995S Tg was transported to the Golgi and associated with the mildly increased serum Tg levels. Native PAGE and Western blot analysis with anti-Tg antibody showed that C1263R Tg and C1995S Tg form high mol wt aggregates in the ER. Our results suggest that missense mutations that replace cysteine with either arginine or serine cause an abnormal three-dimensional structure of Tg. Such misfolded Tg polypeptides are retained in the ER as high mol wt aggregates.

Regulation of insulin-like growth factor I (IGF-I) bioactivity in vivo: further characterization of an IGF-I-enhancing antibody.

We have previously demonstrated the ability of a polyclonal antibody raised against human insulin-like growth factor I (IGF-I) to potentiate, rather than inhibit, the growth-promoting activity of IGF-I. The anti-IGF-I Ig had a modest affinity for IGF-I, protected IGF-I from degradation, and reduced the IGF-I clearance rate while allowing efficient transfer of peptide from the circulation, leading to the suggestion that the antiserum might be behaving in an analogous manner to enhancing IGF-binding proteins (IGFBPs). The purpose of these studies was to investigate further the characteristics of this antiserum as a means of assessing the importance of IGF-I associated with circulating high mol wt IGFBPs to serve as a bioavailable reservoir of IGF-I peptide. 1) Epitope scanning using sequential and overlapping peptides spanning the entire length of IGF-I revealed one major linear region of anti-IGF-I Ig binding to IGF-I comprising the C-terminal region of the C-domain and the N-terminal region of the A-domain (Arg36-Ile43), a region not associated with receptor or IGFBP binding. 2) The fact that the antibody could potentiate IGF-I whether administered as a preincubated complex or separately indicated that complex formation could occur in the presence of IGFBPs in vivo. 3) The ability of the antibody to attenuate the acute hypoglycemic actions of IGF-I and LR3IGF-I was assessed by pretreating dwarf rats with either anti-IGF-I Ig or nonimmune Ig; 1 h after s.c. administration of peptide, plasma glucose levels decreased by about 4 mM (P < 0.001) in rats pretreated with nonimmune Ig. The duration of hypoglycemia was more prolonged in the LR3IGF-I-treated rats (P < 0.01). Neither IGF-I or LR3IGF-I induced any decrease in circulating glucose concentrations in the rats pretreated with the anti-IGF-I Ig, suggesting that the antibody gave protection against inappropriate acute IGF-induced hypoglycemia. 4) The potentiating effects of the anti-IGF-I Ig on the anabolic actions of IGF-I and LR3IGF-I were compared in dwarf mice. The anti-IGF-I Ig potentiated the increase in whole body weight gain induced by IGF-I by over 3-fold (P < 0.001), but did not change the anabolic action of LR3IGF-I despite its ability to double circulating levels of both IGF peptides. It is, therefore, possible that part of the mechanism of action of the anti-IGF-I Ig involves transfer of IGF-I to smaller mol wt binding proteins. These data confirm the potential of IGFBP-associated IGF-I to act as a reservoir of peptide and to regulate IGF-I activity in vivo.

Regulation of Insulin-Like Growth Factor I (IGF-I) Bioactivity in Vivo: Further Characterization of an IGF-I-Enhancing Antibody

We have previously demonstrated the ability of a polyclonal antibody raised against human insulin-like growth factor I (IGF-I) to potentiate, rather than inhibit, the growth-promoting activity of IGF-I. The anti-IGF-I Ig had a modest affinity for IGF-I, protected IGF-I from degradation, and reduced the IGF-I clearance rate while allowing efficient transfer of peptide from the circulation, leading to the suggestion that the antiserum might be behaving in an analogous manner to enhancing IGF-binding proteins (IGFBPs). The purpose of these studies was to investigate further the characteristics of this antiserum as a means of assessing the importance of IGF-I associated with circulating high mol wt IGFBPs to serve as a bioavailable reservoir of IGF-I peptide. 1) Epitope scanning using sequential and overlapping peptides spanning the entire length of IGF-I revealed one major linear region of anti-IGF-I Ig binding to IGF-I comprising the C-terminal region of the C-domain and the N-terminal region of the A-domain (Arg36-Ile43), a region not associated with receptor or IGFBP binding. 2) The fact that the antibody could potentiate IGF-I whether administered as a preincubated complex or separately indicated that complex formation could occur in the presence of IGFBPs in vivo. 3) The ability of the antibody to attenuate the acute hypoglycemic actions of IGF-I and LR3IGF-I was assessed by pretreating dwarf rats with either anti-IGF-I Ig or nonimmune Ig; 1 h after sc administration of peptide, plasma glucose levels decreased by about 4 mm (P < 0.001) in rats pretreated with nonimmune Ig. The duration of hypoglycemia was more prolonged in the LR3IGF-I-treated rats (P < 0.01). Neither IGF-I or LR3IGF-I induced any decrease in circulating glucose concentrations in the rats pretreated with the anti-IGF-I Ig, suggesting that the antibody gave protection against inappropriate acute IGF-induced hypoglycemia. 4) The potentiating effects of the anti-IGF-I Ig on the anabolic actions of IGF-I and LR3IGF-I were compared in dwarf mice. The anti-IGF-I Ig potentiated the increase in whole body weight gain induced by IGF-I by over 3-fold (P < 0.001), but did not change the anabolic action of LR3IGF-I despite its ability to double circulating levels of both IGF peptides. It is, therefore, possible that part of the mechanism of action of the anti-IGF-I Ig involves transfer of IGF-I to smaller mol wt binding proteins. These data confirm the potential of IGFBP-associated IGF-I to act as a reservoir of peptide and to regulate IGF-I activity in vivo.

The biological and immunological characterization of inhibin A and B forms in human follicular fluid and plasma.

In a previous study (see Ref.7), the molecular weight distribution of inhibin activity in fractionated human follicular fluid (hFF) and human male and female plasma/serum was determined by in vitro bioassay using ovine pituitary cells in culture and various specific inhibin A and inhibin alpha-subunit-directed immunoassays. It was shown, however, that the ovine in vitro bioassay detected inhibin B poorly. These findings are extended in the present study by the determination of the molecular weight profile of in vitro bioactivity using rat pituitary cells, which detects both inhibin A and B, a specific inhibin B enzyme-linked immunosorbent assay (ELISA), an RIA detecting the alpha N region of the alpha-subunit, an alpha-subunit ELISA (Pro-alpha C) directed to the inhibin forms containing the Pro sequence, and an alpha C subunit immunofluorometric assay that detects all inhibin forms. The profile in hFF of inhibin in vitro bioactivity, using rat pituitary cells in culture, significantly (P < 0.001) correlated with in vitro bioactivity using ovine pituitary cells (r = 0.85), inhibin A immunoactivity (r = 0.70), inhibin B immunoactivity (r = 0.89), and the combination of inhibin A + B immunoactivities (r = 0.93), with peaks of activity identified at 66K, 55K, 36K and 33K, consistent with presumed known mol wt forms of inhibin. Inhibin B profiles in fractionated serum from women stimulated with gonadotropins and male plasma consisted of two forms (66K and 36K), whereas inhibin A in female serum included, in addition, the 55K form. These findings indicated that higher molecular weight forms of inhibin B are present in biological samples, and their distribution differs from that of inhibin A, suggesting a differential processing of the precursor forms in the circulation. Pro-alpha C immunoactivity was identified in serum samples with prominent peaks at 36K and 29K (known Pro-alpha C subunit forms) and not with any high mol wt dimeric forms of inhibin. If this observation applies to a wider range of serum samples, the Pro-alpha C ELISA may provide an appropriate and specific assay for the measurement of free alpha-subunit. To compare immunoactivity levels between assays, the inhibins A, B, and Pro-alpha C standards were calibrated in terms of their alpha C subunit content, as determined by an alpha C subunit immunoassay, with the inhibin B standard containing 60% of the alpha C subunit content compared with either the inhibin A or Pro-alpha C standard. After adjustments of the various standards for this difference in alpha C subunit content, a comparison was undertaken of the combined levels of inhibins A, B, and Pro-alpha C immunoactivity across the hFF and serum chromatograms and compared with levels determined by the alpha-subunit-directed immunoassays. A high correlation (r = 0.59-0.96) was observed, indicating that the alpha-subunit immunoactivity in serum consists largely of a composite of presumed known molecular weight forms of inhibins A, B, and Pro-alpha C. It is concluded that: 1) inhibin in vitro bioactivity in hFF is largely attributed to the presence of 33-36K and 50-66K forms of inhibins A and B; and 2) inhibin alpha-subunit immunoactivity in hFF and serum is a composite of presumed known forms of inhibin A, inhibin B, and the alpha-subunit.